Stockscreener 앱 받기
75.25
0.27%
-0.20
시간 외 거래:
75.25
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
MSN Money - MSN
Form 144: Option exercises listed; Joseph Loscalzo sold shares (IONS) - Stock Titan
Ionis well-positioned for continued momentum and substantial valu - The National Law Review
Ionis to host 2026 virtual Annual Meeting of Stockholders - BioSpace
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market - openPR.com
Ionis (IONS) Q1 2026 Earnings Call Transcript - AOL.com
Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks - TipRanks
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kornitzer Capital Management Inc. KS Buys Shares of 29,105 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Discipline and Rules-Based Execution in IONS Response - Stock Traders Daily
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
VY(R) T. Rowe Price Diversified Mid Cap Growth Portfolio's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus
Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Teladoc (TDOC) - The Globe and Mail
Ionis Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Ionis to present at upcoming investor conferences - The National Law Review
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold - Moomoo
Vanguard Group Inc. Sells 41,271 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Ionis Pharmaceuticals (IONS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
IONS Maintained by Barclays -- Price Target Raised to $115 - GuruFocus
Atle Fund Management AB's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus
Ionis Pharmaceuticals Projects Ozarsen Sales Exceeding 3 Billion Dollars - HarianBasis.co
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan
Hereditary Angioedema Market: Rapid Increment Driven by Innovation by 2034DelveInsight - openPR.com
Narrow-Moat Ionis' Peak Sales Raised for Olezarsen; Positive Outlook as Late-Stage Assets Advance - Morningstar
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
IONS Maintained by RBC Capital -- Price Target Raised to $100 - GuruFocus
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating - marketscreener.com
Vanguard reports 5.05% stake in Ionis Pharmaceuticals (NASDAQ: IONS) - Stock Titan
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View - TradingView
Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $86 - Moomoo
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $100 to $125 - Moomoo
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2026 Earnings Call Transcript - Insider Monkey
Ionis Pharmaceuticals Q1 2026 earnings preview - MSN
IONS Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans - GuruFocus
Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity By Investing.com - Investing.com India
IONS SWOT Analysis: Strong Revenue Growth Amidst Challenges Reve - GuruFocus
Ionis Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IONS) 2026-04-29 - Seeking Alpha
Oppenheimer raises Ionis Pharmaceuticals price target on guidance By Investing.com - Investing.com Canada
Stifel raises Ionis Pharmaceuticals price target on sHTG opportunity - Investing.com
Ionis outlines 2026 revenue of $875M-$900M while lifting olezarsen peak sales view to >$3B - MSN
Ionis Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Ionis Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c) - TipRanks
Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Issues Quarterly Earnings Results - MarketBeat
Ionis gains on late-stage trial win for hypertriglyceridemia therapy - MSN
Ionis Pharmaceuticals Q1: Revenue $246.1M, EPS (loss) $0.56 — 10-Q Summary - TradingView
Ionis Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Ionis (NASDAQ: IONS) Q1 2026 revenue jumps as net loss shrinks - Stock Titan
Earnings call transcript: Ionis Pharmaceuticals beats Q1 2026 forecasts By Investing.com - Investing.com Nigeria
Ionis (IONS) Reports Strong Q1 Revenue and Upcoming Key Developm - GuruFocus
0.14%
0.48%
자본화:
|
볼륨(24시간):